Goldman Sachs cuts target for Fresenius Medical Care stock to EUR 38.00

Published on 10/06/2026 at 13:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Berenberg cut target from EUR 60.00 to EUR 42.00 on September 29, 2026. Fresenius Medical Care stock costs EUR 40.43 on October 6, 2026, vs. EUR 40.34.

Isometrischer 3D-Render eines Dialysezentrums mit Patientenliegen, Maschinen und Personal — Ein isometrischer 3D-Render eines Miniatur-Dialysezentrums mit Patientenliegen, Geräten und Pflegepersonal – ein anschauliches Modell der Behandlungsstruktur, die Fresenius Medical Care AG (ISIN DE0005785802) weltweit betreibt, Illustration mit AI erstellt.

Fresenius Medical Care (ISIN DE0005785802) is covered by a Goldman Sachs target of EUR 38.00, cut from EUR 39.00 in a September 30, 2026 note published by FinanzNachrichten.de. Goldman Sachs kept its Neutral rating and cited modest expected treatment-volume growth ahead of the November 3, 2026 quarterly report.

Analyst targets move lower

The latest analyst actions give FMC a mixed valuation signal. On September 29, 2026, Berenberg cut its target from EUR 60.00 to EUR 42.00 and downgraded the shares from Buy to Hold, according to finanzen.at.

That EUR 42.00 target stands 3.88 percent above the Lang & Schwarz price of EUR 40.43. Goldman Sachs takes the opposite route on the rating question by retaining Neutral while reducing its target by EUR 1.00, a sharper near-term caution than the operating update alone would suggest.

First-half execution offers support

Operationally, the company reported a 34 percent improvement in underlying operating result in the first half of 2026 and confirmed its 2026 outlook, according to Fresenius Medical Care. The result was attributed to higher reimbursement rates and positive revenue-cycle-management effects in Care Delivery.

The operating details also provide scale for the strategy. The 5008X CAREsystem was available in 227 US clinics and had been used in more than 600,000 treatments, according to the same investor overview from Fresenius Medical Care. For investors, the key test is whether treatment-volume growth can improve while the company protects the first-half operating gains.

November report sets the next test

Fresenius Medical Care has scheduled its third-quarter 2026 reporting for November 3, 2026, followed by publication of the quarterly financial report on November 6, 2026, according to Fresenius Medical Care. Goldman Sachs expects adjusted operating result of EUR 524.00 million, slightly above consensus, while its treatment-volume view remains cautious.

Stock holds above prior close

At Lang & Schwarz, Fresenius Medical Care stock was trading at EUR 40.43 on October 6, 2026 at 1:39 p.m. CEST, plus 0.22 percent versus the prior close of EUR 40.34 on October 5, 2026. The further course of trading is shown by the continuously updated real-time quote of Fresenius Medical Care stock.